Fresh analysis indicates that individuals who stop using popular weight-loss injections like Wegovy and Mounjaro may regain shed pounds far faster than those who halt traditional lifestyle plans.
Findings released in a prominent health publication demonstrates that while obese people frequently drop substantial amounts of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals using such medications must be informed of the danger of quick weight regain when the treatment ends," warns expert Dr. Susan Jebb.
This pace of regain means a reversion to starting mass in about 18 months.
Comparing Treatments
The study, which looked at dozens of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with other pills.
Scientists emphasize that people who shed pounds through diet and exercise typically experience a less rapid creep back—approximately 0.1 kg a month—once they finish.
The Reason for the Fast Rebound
Experts believe the mode of action of the jabs accounts for the accelerated rebound.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than normal could lead to the body to produce less of its own natural GLP-1, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication leads to appetite is no longer kept in check, making binge eating much more probable."
A Lifelong Condition?
Medical guidelines suggest the injections for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
Professionals say that, due to the high risk of relapse, the treatment is often life-long.
This opinion is reinforced by pharmaceutical companies, who note that the findings "emphasize the persistent nature of obesity," similar to managing conditions like high blood pressure.
User Experiences
People who have stopped the medication explain a sudden return of cravings.
"It was like something that goes on and I was suddenly starving," said an individual.
The struggle is worsened if individuals have not developed lasting dietary or behavioural changes during treatment.
Widespread Interest
Survey data suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Use is greater among females than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, experts emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a magic cure and long-term success relies on integrated behavioural changes.
